What side effects are associated with this type of intervention?

Common treatments for Multiple Myeloma, particularly those similar to BCMA-directed CAR-T cell therapy like anitocabtagene-autoleucel, include CAR-T cell therapies and other immunotherapies. Known side effects of these treatments can include cytokine release syndrome (CRS), which may cause fever, low blood pressure, and difficulty breathing. Neurological toxicities are also common, potentially leading to confusion, seizures, or encephalopathy. Other side effects may include infections due to immunosuppression, cytopenias (low blood cell counts), and organ toxicities. It is crucial for patients to discuss these potential risks with their healthcare provider to make an informed decision.

What prior FDA approvals exist?

The FDA has approved several treatments for Multiple Myeloma, including BCMA-directed therapies such as idecabtagene vicleucel and ciltacabtagene autoleucel, which are chimeric antigen receptor (CAR) T cell therapies. Additionally, the anti-BCMA antibody drug conjugate belantamab mafodotin has been approved. Other related treatments include proteasome inhibitors like bortezomib and carfilzomib, immunomodulatory drugs such as lenalidomide and pomalidomide, and monoclonal antibodies like daratumumab and elotuzumab.

What other types of research exist?

Promising alternatives to Anitocabtagene-autoleucel for Multiple Myeloma patients include: 1) Other BCMA-directed CAR-T cell therapies such as idecabtagene vicleucel and ciltacabtagene autoleucel. 2) Bispecific antibodies like teclistamab, which targets both BCMA and CD3. 3) Novel drug combinations such as selinexor, bortezomib, and dexamethasone, which have shown efficacy in relapsed or refractory multiple myeloma.

← Back to Search

CAR T-cell Therapy

CART-ddBCMA for Multiple Myeloma (iMMagine-1 Trial)

Phase 2

Recruiting

Research Sponsored by Kite, A Gilead Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Summary

This trial is testing a new cancer treatment that uses a patient's own immune cells to target and destroy cancer cells.

Who is the study for?

Adults with relapsed or refractory multiple myeloma who have tried at least three prior treatments, including proteasome inhibitors, IMiDs, and anti-CD38 antibodies. They must show measurable disease signs, be in good physical condition (ECOG 0-1), have a life expectancy over 12 weeks, and proper organ function. Participants should not be pregnant or breastfeeding and must agree to use effective birth control for a year post-treatment.Check my eligibility

What is being tested?

The trial is testing CART-ddBCMA, which is a type of CAR-T cell therapy targeting BCMA on cancer cells. It's for patients whose multiple myeloma has returned after treatment or hasn't responded to standard therapies. The study will assess the safety and effectiveness of this new intervention.See study design

What are the potential side effects?

CAR-T cell therapies like CART-ddBCMA can cause cytokine release syndrome (flu-like symptoms such as fever and fatigue), neurological effects (confusion or difficulty speaking), low blood cell counts leading to increased infection risk, bleeding issues, and potential allergic reactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Response Rate (ORR)

Secondary outcome measures

Anti-anitocabtagene-autoleucel Antibodies

Duration of Response (DoR)

Health Related Quality of Life (HRQoL)

+10 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: anitocabtagene-autoleucelExperimental Treatment1 Intervention

Single dose of 115±10 x 10e-6 CAR+ anitocabtagene-autoleucel cells infused intravenously

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Multiple Myeloma treatments target the malignant plasma cells through various mechanisms. Proteasome inhibitors (e.g., bortezomib) disrupt protein degradation, leading to cell death. Immunomodulatory drugs (e.g., lenalidomide) enhance immune response and inhibit tumor growth. Monoclonal antibodies (e.g., daratumumab) target specific antigens on myeloma cells, marking them for destruction by the immune system. BCMA-directed CAR-T cell therapies, like Anitocabtagene-autoleucel, genetically modify a patient's T cells to target and kill myeloma cells expressing the BCMA protein. These treatments are crucial as they offer targeted, effective options for managing and potentially eradicating Multiple Myeloma, improving patient outcomes and survival rates.

Find a Location

Who is running the clinical trial?

Multiple Myeloma Research FoundationOTHER

10 Previous Clinical Trials

3,467 Total Patients Enrolled

10 Trials studying Multiple Myeloma

3,467 Patients Enrolled for Multiple Myeloma

Kite, A Gilead CompanyLead Sponsor

44 Previous Clinical Trials

3,966 Total Patients Enrolled

4 Trials studying Multiple Myeloma

548 Patients Enrolled for Multiple Myeloma

Arcellx, Inc.Industry Sponsor

3 Previous Clinical Trials

539 Total Patients Enrolled

2 Trials studying Multiple Myeloma

515 Patients Enrolled for Multiple Myeloma

Media Library

CART-ddBCMA (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05396885 — Phase 2

Multiple Myeloma Research Study Groups: anitocabtagene-autoleucel

Multiple Myeloma Clinical Trial 2023: CART-ddBCMA Highlights & Side Effects. Trial Name: NCT05396885 — Phase 2

CART-ddBCMA (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05396885 — Phase 2

~38 spots leftby Jul 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.